141 related articles for article (PubMed ID: 22782328)
1. An update on calcium metabolism alterations and cardiovascular risk in patients with chronic kidney disease: questions, myths and facts.
Savica V; Bellinghieri G; Monardo P; Muraca U; Santoro D
J Nephrol; 2013; 26(3):456-64. PubMed ID: 22782328
[TBL] [Abstract][Full Text] [Related]
2. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
Hanafusa N
Clin Calcium; 2015 May; 25(5):711-21. PubMed ID: 25926575
[TBL] [Abstract][Full Text] [Related]
3. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
4. Ten-year experience with sevelamer and calcium salts as phosphate binders.
Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
[TBL] [Abstract][Full Text] [Related]
5. Emerging effects of sevelamer in chronic kidney disease.
Ikee R; Tsunoda M; Sasaki N; Sato N; Hashimoto N
Kidney Blood Press Res; 2013; 37(1):24-32. PubMed ID: 23486088
[TBL] [Abstract][Full Text] [Related]
6. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
[TBL] [Abstract][Full Text] [Related]
7. Optimal use of phosphate binders in chronic kidney disease.
Sonikian M; Papachristou E; Goumenos DS
Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
[TBL] [Abstract][Full Text] [Related]
9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
Koizumi M; Fukagawa M
Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease.
Khouzam N; Wesseling-Perry K
Pediatr Nephrol; 2019 Jan; 34(1):1-10. PubMed ID: 28939921
[TBL] [Abstract][Full Text] [Related]
12. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
13. Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease.
Mason DL; Godugu K; Nnani D; Mousa SA
Clin Transl Sci; 2022 Feb; 15(2):353-360. PubMed ID: 34599865
[TBL] [Abstract][Full Text] [Related]
14. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
Negri AL
J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
[TBL] [Abstract][Full Text] [Related]
15. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
[TBL] [Abstract][Full Text] [Related]
16. [Prevention of cardiovascular comorbidities in uremic patients on chronic dialysis: metabolic derangements and cardiovascular risk].
Malberti F
G Ital Nefrol; 2012; 29 Suppl 58():S61-7. PubMed ID: 23229605
[TBL] [Abstract][Full Text] [Related]
17. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
18. Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.
de Oliveira RB; Graciolli FG; dos Reis LM; Cancela AL; Cuppari L; Canziani ME; Carvalho AB; Jorgetti V; Moysés RM
Nephrol Dial Transplant; 2013 Oct; 28(10):2510-7. PubMed ID: 23975746
[TBL] [Abstract][Full Text] [Related]
19. Role of uremic toxins and oxidative stress in the development of chronic kidney disease-mineral and bone disorder.
Tanaka H; Komaba H; Koizumi M; Kakuta T; Fukagawa M
J Ren Nutr; 2012 Jan; 22(1):98-101. PubMed ID: 22200424
[TBL] [Abstract][Full Text] [Related]
20. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.
Liu L; Wang Y; Chen H; Zhu X; Zhou L; Yang Y
Ren Fail; 2014 Sep; 36(8):1244-52. PubMed ID: 25019348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
